Zevra Therapeutics (ZVRA) Stock Price, News & Analysis

Company Overview

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat. Niemann-Pick disease type C is a rare, progressive genetic disorder that affects the body’s ability to transport and process cholesterol and other lipids within cells.

The company was formed through the combination of Acer Therapeutics and KemPharm, completed in 2023. Zevra is headquartered in the United States and initially focuses its commercial activities on the U.S. rare-disease market, while continuing to advance additional development programs for serious and underserved conditions.

Key Stats

• Today's Range: $10.00 to $10.81
• 50-Day Range: $9.51 to $12.68
• 52-Week Range: $8.01 to $15.03
• Volume: 1.98 million shs
• Average Volume: 911,152 shs
• Market Capitalization: $635.37 million
• P/E Ratio: 11.63
• Dividend Yield: N/A
• Price Target: $27.14
• Consensus Rating: Buy

Zevra Therapeutics Stock Analysis - MarketRank™

Zevra Therapeutics scored higher than 90% of companies evaluated by MarketBeat, and ranked 31st out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Zevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Zevra Therapeutics has a consensus price target of $27.14, representing about 153.7% upside from its current price of $10.70.

Amount of Analyst Coverage

Zevra Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 16.67%

Earnings Growth

Earnings for Zevra Therapeutics are expected to grow by 16.67% in the coming year, from $0.72 to $0.84 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zevra Therapeutics is 11.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zevra Therapeutics is 11.63, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.34.

Price to Book Value per Share Ratio

Zevra Therapeutics has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.03% of the float of Zevra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Zevra Therapeutics has a short interest ratio ("days to cover") of 6.33.

Change versus previous month

Short interest in Zevra Therapeutics has recently decreased by 0.56%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zevra Therapeutics does not currently pay a dividend.

Dividend Growth

Zevra Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.84

News Sentiment

Zevra Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Zevra Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for ZVRA on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Zevra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $138,375.00 in company stock.

Percentage Held by Insiders

3.70% of the stock of Zevra Therapeutics is held by insiders.

Percentage Held by Institutions

35.03% of the stock of Zevra Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ZVRA
• CIK: 1434647
• Web: www.zevra.com
• Phone: (321) 939-3416
• Fax: 319-665-2577
• Employees: 61
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Zevra Therapeutics: $27.14
• High Price Target: $35.00
• Low Price Target: $20.00
• Potential Upside/Downside: +153.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.92
• Trailing P/E Ratio: 11.63
• Forward P/E Ratio: 14.86
• P/E Growth: N/A
• Net Income: $83.23 million
• Net Margins: 42.82%
• Pretax Margin: 50.92%
• Return on Equity: 54.54%
• Return on Assets: 34.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.17
• Quick Ratio: 5.12

Sales & Book Value

• Annual Sales: $106.47 million
• Price / Sales: 5.97
• Cash Flow: $1.01 per share
• Price / Cash Flow: 10.56
• Book Value: $2.75 per share
• Price / Book: 3.89

Miscellaneous

• Outstanding Shares: 59,380,000
• Free Float: 57,187,000
• Market Cap: $635.37 million
• Optionable: Optionable
• Beta: 0.98